Currently, Rapport Therapeutics Inc [RAPP] is trading at $16.37, down -7.15%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RAPP shares have gain 11.89% over the last week, with a monthly amount glided 15.69%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rapport Therapeutics Inc [NASDAQ: RAPP] stock has seen the most recent analyst activity on August 06, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $31. On July 02, 2024, TD Cowen initiated with a Buy rating. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $35 on July 02, 2024. Jefferies initiated its recommendation with a Buy and recommended $35 as its price target on July 02, 2024.
This stock has fluctuated between a low of $6.43 and a high of $29.74 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Rapport Therapeutics Inc [NASDAQ: RAPP] shares were valued at $16.37 at the most recent close of the market. An investor can expect a potential return of 113.81% based on the average RAPP price forecast.
Analyzing the RAPP fundamentals
Gross Profit Margin for this corporation currently stands at -0.49% with Operating Profit Margin at -141.34%, Pretax Profit Margin comes in at -122.66%, and Net Profit Margin reading is -122.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.3 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.88 points at the first support level, and at 13.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.78, and for the 2nd resistance point, it is at 19.19.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Rapport Therapeutics Inc [NASDAQ:RAPP] is 22.75. Further, the Quick Ratio stands at 22.75, while the Cash Ratio is 4.64.
Transactions by insiders
Recent insider trading involved Bredt David, Chief Scientific Officer, that happened on Aug 15 ’25 when 8500.0 shares were sold. Chief Scientific Officer, Bredt David completed a deal on Jul 15 ’25 to sell 8500.0 shares. Meanwhile, Chief Scientific Officer Bredt David sold 8500.0 shares on Jun 16 ’25.
